Widesott Lamberto, Amichetti Maurizio, Schwarz Marco
ATreP-Provincial Agency for Proton Therapy, Trento, Italy.
Radiother Oncol. 2008 Feb;86(2):154-64. doi: 10.1016/j.radonc.2008.01.003. Epub 2008 Jan 31.
To determine whether, according to the currently available literature, proton therapy (PT) has a role in the treatment of non-small-cell lung cancer (NSCLC), to assess its safety and efficacy and to evaluate the main technical issues specifically related to this treatment technique.
During March 2007, two independent researchers conducted a systematic review of the current data on the treatment of NSCLC with PT.
In total, 113 reports were retrieved, 17 of which were included in the analysis. There were no prospective trials (randomized or non-randomized). Nine uncontrolled single-arm studies were available from three PT centers, providing clinical outcomes for 214 patients in total. These reports were mainly related to stage I-II tumors, with results comparable to those obtained with surgery, without significant toxicity. In addition, two papers were found that compared photon and proton dose distributions, which showed a potential for dose escalation and/or a sparing of the organ at risk with PT. Finally, six studies analyzed dosimetric and technical issues related with PT, mainly underlining the difficulties in designing dose distributions that are representative of the dose actually delivered during treatment.
Although from a physical point of view PT is a good option for the treatment of NSCLC, limited data are available on its application in the clinical practice. Furthermore, the application of PT to lung cancer does present technical challenges. Because of the small number of institutions involved in the treatment of this disease, number of patients, and methodological weaknesses of the trials it is therefore not possible to draw definitive conclusions about the superiority of PT with respect to the photon techniques currently available for the treatment of NSCLC.
根据现有文献,确定质子治疗(PT)在非小细胞肺癌(NSCLC)治疗中是否具有作用,评估其安全性和有效性,并评估与该治疗技术特别相关的主要技术问题。
2007年3月,两名独立研究人员对目前关于PT治疗NSCLC的数据进行了系统评价。
共检索到113篇报告,其中17篇纳入分析。没有前瞻性试验(随机或非随机)。来自三个PT中心的9项非对照单臂研究可用,总共为214例患者提供了临床结果。这些报告主要涉及I-II期肿瘤,结果与手术相当,无明显毒性。此外,发现两篇比较光子和质子剂量分布的论文,显示PT有剂量递增和/或保护危险器官的潜力。最后,六项研究分析了与PT相关的剂量学和技术问题,主要强调了设计代表治疗期间实际给予剂量的剂量分布的困难。
尽管从物理角度来看,PT是治疗NSCLC的一个好选择,但关于其在临床实践中的应用的数据有限。此外,PT应用于肺癌确实存在技术挑战。由于参与该疾病治疗的机构数量、患者数量以及试验的方法学缺陷,因此无法就PT相对于目前可用于治疗NSCLC的光子技术的优越性得出明确结论。